Biden Administration's Negotiation on Medicine Prices with Big Pharma under Medicare / Quazi T. Islam.

Format:

Book

Author/Creator:

Islam, Quazi T., author.

Alam, Shafquat Rafiul, author.

Singh, Tilottama, author.

Goel, Richa, 1980- author.

Series:

SAGE business cases.

SAGE business cases

Language:

English

Subjects (All):

Mediation and conciliation, Criminal--Argentina.

Mediation and conciliation, Criminal.

Physical Description:

1 online resource

Place of Publication:

London : SAGE Publications: SAGE Business Cases Originals, 2025.

Summary:

In this case study, the U.S. healthcare system is examined, focusing on Medicare and the recent challenges it faces, especially in terms of rising prescription drug costs. As students explore this case, they will delve into the historical development of Medicare, examine its key components, and investigate the complexities involved in its operation. The core of this study revolves around the recent initiatives by the Biden administration to negotiate lower drug prices, highlighting the conflict between healthcare affordability and pharmaceutical innovation. Through this case, students will engage in an analysis of the strategies employed by both the government and pharmaceutical companies, understanding their impacts on public policy and healthcare economics. This case offers a practical perspective into the real-world dynamics of healthcare management, encouraging students to apply business principles to analyze and propose solutions to current challenges in the U.S. healthcare sector. Students will be asked to devise a strategic plan to address the challenge of escalating prescription drug costs under Medicare, analyzing the balance between ensuring affordable healthcare for beneficiaries and maintaining the financial incentives necessary for pharmaceutical innovation. They will apply business concepts such as stakeholder analysis, cost-benefit analysis, and negotiation strategies to evaluate the potential impacts of policy changes on different stakeholders, including the government, pharmaceutical companies, and the general public.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

9781071959060

1071959069

OCLC:

1483992799